Oxford Asset Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Oxford Asset Management’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-261,538	Closed	-$15.7M	–	1717
2019 Q4	$15.7M	Buy	261,538 +218,158	+503%	+$8.19M	0.43%	24
2019 Q3	$1.22M	Buy	43,380 +19,245	+80%	+$657K	0.03%	829
2019 Q2	$914K	Sell	24,135 -12,192	-34%	-$468K	0.02%	1018
2019 Q1	$1.42M	Buy	+36,327	New	+$1.04M	0.03%	766
2018 Q3	–	Sell	-10,939	Closed	-$414K	–	2062
2018 Q2	$414K	Sell	10,939 -6,198	-36%	-$230K	0.01%	1409
2018 Q1	$515K	Buy	+17,137	New	+$580K	0.01%	1236
2017 Q3	–	Sell	-22,398	Closed	-$428K	–	1796
2017 Q2	$428K	Buy	+22,398	New	+$358K	0.01%	1155

Oxford Asset Management's BOLD Position: Q1 2020 in Review

Oxford Asset Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 261,538 shares — an estimated $15.7M sold.

Oxford Asset Management first reported a position in BOLD in Q2 2017 and held it in 7 quarters. The position peaked at $15.7M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Oxford Asset Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 261,538 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $15.7M.
Oxford Asset Management first reported a position in Audentes Therapeutics, Inc in Q2 2017 and held it in 7 quarters.
Oxford Asset Management's Audentes Therapeutics, Inc position peaked at $15.7M in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.